<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04654221</url>
  </required_header>
  <id_info>
    <org_study_id>QRK509</org_study_id>
    <nct_id>NCT04654221</nct_id>
  </id_info>
  <brief_title>Evaluation of Renal Function in Subjects Who Had Undergone Cardiac Surgery</brief_title>
  <official_title>Evaluation of eGFR, Determined by Cystatin C and Creatinine, and mGFR, Measured by Iohexol Clearance, in Subjects at High Risk for Acute Kidney Injury (AKI) Following Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Quark Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Quark Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the differences between serum cystatin C based estimated glomerular filtration&#xD;
      rate (eGFRcys), serum creatinine based eGFR (eGFRcreat) and measured glomerular filtration&#xD;
      rate (mGFR) in subjects at high risk for acute kidney injury (AKI) approximately 90 days&#xD;
      following cardiac surgery&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, single-visit study to evaluate the relationship between mGFR and eGFR&#xD;
      based either on serum creatinine (eGFRcreat) or cystatin C (eGFRcys) approximately 90 days&#xD;
      following cardiac surgery. No investigational study drug will be administered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated early due to program discontinuation.&#xD;
  </why_stopped>
  <start_date type="Actual">February 21, 2020</start_date>
  <completion_date type="Actual">March 26, 2021</completion_date>
  <primary_completion_date type="Actual">February 25, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between eGFR and mGFR</measure>
    <time_frame>at 90 days post cardiac surgery</time_frame>
    <description>The primary measure will be the comparison of the P(30) and P(10) between eGFR based on serum cystatin C (eGFRcys) and eGFR based on serum creatinine (eGFRcreat). P(30) and P(10) are defined as the percentage of subjects whose eGFR is within 30% (10%) of the iohexol-based mGFR.</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Actual">16</enrollment>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Male, BMI &lt;= 24.9</arm_group_label>
    <description>Male subjects with a BMI of less than or equal to 24.9</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Female, BMI &lt;= 24.9</arm_group_label>
    <description>Female subjects with a BMI of less than or equal to 24.9</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Male, BMI 25-29</arm_group_label>
    <description>Male subjects with a BMI of 25 to 29</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Female, BMI 25-29</arm_group_label>
    <description>Female subjects with a BMI of 25 to 29</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Male, BMI &gt;29</arm_group_label>
    <description>Male subjects with a BMI of greater than 29</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Female, BMI &gt;29</arm_group_label>
    <description>Female subjects with a BMI of greater than 29</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>mGFR by iohexol clearance</intervention_name>
    <description>Iohexol 5mL injection (300 mg iodine/mL) will be administered to all subjects to determine mGFR by iohexol clearance</description>
    <arm_group_label>Female, BMI 25-29</arm_group_label>
    <arm_group_label>Female, BMI &lt;= 24.9</arm_group_label>
    <arm_group_label>Female, BMI &gt;29</arm_group_label>
    <arm_group_label>Male, BMI 25-29</arm_group_label>
    <arm_group_label>Male, BMI &lt;= 24.9</arm_group_label>
    <arm_group_label>Male, BMI &gt;29</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who have undergone non-emergent cardiac surgery and were at high risk of&#xD;
        developing AKI, who meet all of the Inclusion and none of the Exclusion criteria, will be&#xD;
        eligible.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, age â‰¥ 45 years old&#xD;
&#xD;
          -  At risk for AKI following cardiac surgery on the basis of at least one of the&#xD;
             following pre-operatively assessed risk factors:&#xD;
&#xD;
               1. Reduced renal function&#xD;
&#xD;
               2. Diabetes with ongoing insulin treatment&#xD;
&#xD;
               3. Albuminuria&#xD;
&#xD;
          -  Have undergone non-emergent open chest cavity cardiovascular surgeries, with use of&#xD;
             cardiopulmonary bypass (CPB), with or without hypothermic circulatory arrest&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Emergent surgeries, including aortic dissection, and major congenital heart defects&#xD;
&#xD;
          -  Past cardiac surgery off CPB&#xD;
&#xD;
          -  Have a known allergy to iohexol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nitsan Halevy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Quark Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CB Flock Research</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Clinical Trials</name>
      <address>
        <city>Covina</city>
        <state>California</state>
        <zip>91723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Clinical Trials</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multi-Specialty Research Associates, Inc.</name>
      <address>
        <city>Lake City</city>
        <state>Florida</state>
        <zip>32055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advance Medical Research</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 27, 2020</study_first_submitted>
  <study_first_submitted_qc>November 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GFR</keyword>
  <keyword>Acute Kidney Injury</keyword>
  <keyword>AKI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

